Boston Scientific Corporation (BSX) Stock Score, Valuation & Financial Research
Boston Scientific Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 57/100.
Quick answer for BSX
Boston Scientific Corporation currently has a Wall Street Score of 57/100. The stored market price is $45.05. Its financial score is 25/100. Its valuation score is 93/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Boston Scientific Corporation does
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treati
BSX financial snapshot
- Wall Street Score:
- 57/100
- Current price:
- $45.05
- Market capitalization:
- $66.96B
- Revenue:
- $21.00B
- Net income:
- $3.67B
- Free cash flow:
- $3.66B
- Cash:
- $539.0M
- Total debt:
- $12.62B
- EPS:
- 2.48
- P/E ratio:
- 18.2x
- Financial score:
- 25/100
- Valuation score:
- 93/100
- Revenue score:
- 35/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $3.66B, showing positive cash generation.
- The balance sheet shows $539.0M of cash versus $12.62B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.4 points: BSX increased 0.4 points because Capital improved by 3 points.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BSX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.